Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent Oxyrase on in vitro activities of tigecycline against recent clinical isolates

被引：40

作者：

Petersen, PJ ^{[1
]}

Bradford, PA ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Pearl River, NY 10965 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2005年 / 49卷 / 09期

关键词：

D O I：

10.1128/AAC.49.9.3910-3918.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In determining the quality control limits for the Clinical Laboratory Standards Institute-recommended quality control organisms with tigecycline, a number of inconsistencies in the results were encountered that appeared to be related to the age of the Mueller-Hinton broth II. This study was performed to examine the effect of medium age and supplementation with Oxyrase on the activity of tigecycline using a large number of clinical isolates.

引用

收藏

页码：3910 / 3918

页数：9

相关论文

共 14 条

[1] In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].

Boucher, HW ;

Wennersten, CB ;

Eliopoulos, GM .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229

[2] Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].

Bradford, PA .

CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951

[3]

BRADFORD PA, IN PRESS ANTIMICROB

[4]

*CLIN LAB STAND I, 2005, M100S15 CLIN LAB S15, V25

[5] Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates [J].

Gales, AC ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (01) :19-36

[6] Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis [J].

Lefort, AS ;

Lafaurie, M ;

Massias, L ;

Petegnief, Y ;

Saleh-Mghir, A ;

Muller-Serieys, C ;

Le Guludec, D ;

Fantin, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :216-222

[7] Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates [J].

Milatovic, D ;

Schmitz, FJ ;

Verhoef, J ;

Fluit, AC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :400-404

[8] Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis [J].

Murphy, TM ;

Deitz, JM ;

Petersen, PJ ;

Mikels, SM ;

Weiss, WJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3022-3027

[9]

*NAT COMM CLIN LAB, 2003, M7A6 NAT COMM CLIN L, V23

[10] In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) [J].

Petersen, PJ ;

Jacobus, NV ;

Weiss, WJ ;

Sum, PE ;

Testa, RT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (04) :738-744